SELLAS Life Sciences Group Inc.'s galinpepimut-S met its main goal of prolonging the life of patients in a phase 2 trial for a certain type of blood and bone marrow cancer.
Results from the trial showed galinpepimut-S, a peptide vaccine, prolonged the lives of patients with acute myeloid leukemia. In the study, the percentage of people on the drug who were still alive at three years was 47.4%.
In addition, people in the study remained free of the disease for a median of 16.9 months.
The treatment was well-received, with the most common side effects being injection site reactions, fatigue and hardening of the skin.
The New York-based biopharmaceutical company said galinpepimut-S is planned for phase 3 clinical trials in acute myeloid leukemia and malignant pleural mesothelioma, a form of lung cancer. The company is also developing the therapy as a potential treatment for multiple myeloma, a cancer of plasma cells, and ovarian cancer.
The U.S. Food and Drug Administration and the European Medicines Agency granted orphan drug status for galinpepimut-S in acute myeloid leukemia and malignant pleural mesothelioma. The treatment also received fast-track status for those indications from the FDA.